BNP Paribas Financial Markets Purchases Shares of 158,017 Bioventus Inc. (NYSE:BVS)

BNP Paribas Financial Markets acquired a new stake in shares of Bioventus Inc. (NYSE:BVS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 158,017 shares of the company's stock, valued at approximately $1,659,000. BNP Paribas Financial Markets owned about 0.19% of Bioventus at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. HighTower Advisors LLC raised its stake in shares of Bioventus by 11.3% in the fourth quarter. HighTower Advisors LLC now owns 13,617 shares of the company's stock worth $143,000 after buying an additional 1,380 shares during the period. Principal Financial Group Inc. increased its stake in Bioventus by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 19,228 shares of the company's stock worth $202,000 after acquiring an additional 1,652 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Bioventus by 106.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock worth $36,000 after acquiring an additional 1,786 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Bioventus by 26.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,194 shares of the company's stock worth $160,000 after acquiring an additional 3,153 shares during the last quarter. Finally, Plato Investment Management Ltd bought a new stake in Bioventus in the 4th quarter worth approximately $38,000. Institutional investors own 62.94% of the company's stock.

Bioventus Stock Up 0.3%

NYSE BVS traded up $0.02 on Friday, reaching $6.53. 587,066 shares of the stock traded hands, compared to its average volume of 456,759. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The company has a fifty day moving average price of $7.79 and a 200-day moving average price of $9.63. The company has a market cap of $536.40 million, a price-to-earnings ratio of -10.70 and a beta of 0.95. Bioventus Inc. has a 12 month low of $5.28 and a 12 month high of $14.38.

Analyst Ratings Changes

A number of brokerages have recently commented on BVS. Canaccord Genuity Group reiterated a "buy" rating and issued a $15.00 target price on shares of Bioventus in a report on Monday, March 17th. Craig Hallum set a $15.00 price objective on Bioventus and gave the company a "buy" rating in a report on Wednesday, May 7th.

Insider Buying and Selling at Bioventus

In other Bioventus news, CFO Mark Leonard Singleton sold 5,479 shares of Bioventus stock in a transaction on Monday, March 24th. The stock was sold at an average price of $9.79, for a total transaction of $53,639.41. Following the completion of the sale, the chief financial officer now directly owns 131,963 shares of the company's stock, valued at $1,291,917.77. The trade was a 3.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 13,330 shares of company stock valued at $115,291 in the last ninety days. Corporate insiders own 32.90% of the company's stock.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.